<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02918929</url>
  </required_header>
  <id_info>
    <org_study_id>EDP 305-001</org_study_id>
    <nct_id>NCT02918929</nct_id>
  </id_info>
  <brief_title>A Study of EDP 305 in Healthy Subjects and Subjects With Presumptive NAFLD</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, First-In-Human Study of Orally Administered EDP-305 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses (SAD), Multiple Ascending Doses (MAD) and the Effect of Food on EDP-305 Pharmacokinetics in Healthy Subjects, and of Multiple Ascending Doses (MAD) in Subjects With Presumptive NAFLD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Enanta Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pharmaceutical Research Associates</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Enanta Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, double-blind, placebo-controlled study will assess the safety, tolerability,&#xD;
      and pharmacokinetics of single and multiple orally administered doses of EDP-305 in healthy&#xD;
      adult subjects, and adult subjects with presumptive NAFLD (i.e., obese subjects with or&#xD;
      without prediabetes or T2DM).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The first phase assesses single ascending doses for EDP 305 (active drug or placebo) in&#xD;
      healthy subjects. A &quot;fasted&quot; and &quot;fed&quot; two-part cohort will also assess food effect.&#xD;
&#xD;
      The second phase assesses multiple ascending doses (active drug or placebo) for 14-days in&#xD;
      healthy subjects and also in subjects with presumptive NAFLD (i.e., obese subjects with or&#xD;
      without prediabetes or T2DM).&#xD;
&#xD;
      Each cohort within each phase will enroll a total of 8 subjects who will be randomized to&#xD;
      receive EDP-305 or placebo. The cohort assessing food effect will enroll 10 subjects&#xD;
      randomized to receive EDP-305 or placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety data including but not limited to adverse events, physical exams, vital signs, 12-lead ECGs and clinical lab results (including chemistry, hematology, and urinalysis).</measure>
    <time_frame>From screening to the 7-day post treatment safety follow up visit.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>0 (predose), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 30, 36, 48, 60, 72 (D4), and 96 (D5) hrs post dose.</time_frame>
    <description>EDP 305</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Day 1: 0 (predose), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15 hrs; Days 2, 3, 4, 5, 7, 9, 12; Day 14: 0 (predose), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24 (D15), 30, 36, 48 (D16), 60, 72 (D17), and 96 (D18) hrs postdose</time_frame>
    <description>EDP 305</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>0 (predose), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 30, 36, 48, 60, 72 (D4), and 96 (D5) hrs post dose.</time_frame>
    <description>EDP 305</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>Day 1: 0 (predose), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15 hrs; Days 2, 3, 4, 5, 7, 9, 12; Day 14: 0 (predose), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24 (D15), 30, 36, 48 (D16), 60, 72 (D17), and 96 (D18) hrs postdose</time_frame>
    <description>EDP 305</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from baseline: FGF19</measure>
    <time_frame>Day 1 predose and postdose hours 2, 4, 8, 12, and 24 (i.e., Day 2 predose)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline: C4</measure>
    <time_frame>Day 1 predose and postdose hours 2, 4, 8, 12, and 24 (i.e., Day 2 predose)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline: FGF19</measure>
    <time_frame>Day 1 predose and postdose hours 2, 4, 6, 8, 12 and 24 (i.e., Day 2 predose); Day 7 predose and postdose hours 8, 12, and 24 (i.e., Day 8 predose); Day 14 predose and postdose hours 8, 12, and 24 (i.e., Day 15 predose)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline: C4</measure>
    <time_frame>Day 1 predose and postdose hours 2, 4, 6, 8, 12 and 24 (i.e., Day 2 predose); Day 7 predose and postdose hours 8, 12, and 24 (i.e., Day 8 predose); Day 14 predose and postdose hours 8, 12, and 24 (i.e., Day 15 predose)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline: total bile acids</measure>
    <time_frame>Day 1 predose and approximately 8 to 12 hours postdose</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline: total bile acids</measure>
    <time_frame>Day 1 predose; Day 7 approximately 8 to 12 hours postdose; Day 14 approximately 8 to 12 hours postdose</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">146</enrollment>
  <condition>Presumptive NAFLD</condition>
  <arm_group>
    <arm_group_label>EDP 305 SAD Cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EDP 305 Dose 1, Dose 2, Dose 3, Dose 4, Dose 5, and Dose 6 oral suspension, once daily in one single administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EDP 305 MAD Cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EDP 305 Dose 1, Dose 2, Dose 3, Dose 4, Dose 5 and Dose 6 oral suspension, once daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EDP 305 SAD Placebo Cohort</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo, oral suspension, once daily in one single administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EDP 305 MAD Placebo Cohort</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo, oral suspension, once daily for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EDP 305</intervention_name>
    <arm_group_label>EDP 305 MAD Cohorts</arm_group_label>
    <arm_group_label>EDP 305 SAD Cohorts</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo to match EDP 305</description>
    <arm_group_label>EDP 305 MAD Placebo Cohort</arm_group_label>
    <arm_group_label>EDP 305 SAD Placebo Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for all SAD and MAD Subjects::&#xD;
&#xD;
          -  An informed consent document signed and dated by the subject.&#xD;
&#xD;
          -  Healthy male and female subjects of any ethnic origin between the ages of 18 and 55&#xD;
             years, inclusive.&#xD;
&#xD;
          -  Female subjects must be of non-childbearing potential.&#xD;
&#xD;
          -  All male participants who have not had a vasectomy must use effective contraception&#xD;
             from Day -1 to 90 days after their last dose of study drug.&#xD;
&#xD;
          -  For healthy volunteers only (see below for Subjects with presumptive NAFLD): Body mass&#xD;
             index of 18 to 30 kg/m2 with a minimum body weight of 50 kg.&#xD;
&#xD;
        Additional Inclusion Criteria for MAD Subjects with Presumptive NAFLD:&#xD;
&#xD;
          -  Body mass index of &gt;28 and &lt;35 kg/m2 at screening.&#xD;
&#xD;
        WITH or WITHOUT one of the following:&#xD;
&#xD;
          -  Type 2 diabetes mellitus diagnosed by one of the following methods:&#xD;
&#xD;
               -  As defined by the American Diabetes Association (ADA), as one of the following&#xD;
                  criteria: a) symptoms of diabetes plus casual plasma glucose concentration &gt;200&#xD;
                  mg/dL (11.1 mmol/L) OR b) Fasting plasma glucose &gt;126 mg/dL (7.0 mmol/L) OR c)&#xD;
                  2-hour post-load glucose &gt;200 mg/dL (11.1 mmol/L) during a 75 g oGTT.&#xD;
&#xD;
               -  HbA1c of at least 6.5%. --- OR---&#xD;
&#xD;
          -  Prediabetes diagnosed as defined by the ADA as a) an HbA1c of 5.7% - 6.4% OR b)&#xD;
             fasting blood glucose of 100-125 mg/dL OR c) an oGTT 2-hour blood glucose of 140 mg/dL&#xD;
             - 199 mg/dL.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically relevant evidence or history of illness or disease.&#xD;
&#xD;
          -  Pregnant or nursing females.&#xD;
&#xD;
          -  History of febrile illness within 7 days prior to the first dose of study drug or&#xD;
             subjects with evidence of active infection.&#xD;
&#xD;
          -  A positive urine drug screen at screening or Day -1.&#xD;
&#xD;
          -  Current tobacco smokers or use of tobacco within 3 months prior to screening.&#xD;
&#xD;
          -  Any condition possibly affecting drug absorption (e.g., gastrectomy, cholecystectomy).&#xD;
&#xD;
          -  History of regular alcohol consumption&#xD;
&#xD;
          -  Participation in a clinical trial within 30 days prior to study drug administration.&#xD;
&#xD;
          -  Use of prescription drugs, non-prescription drugs, dietary supplements including&#xD;
             Vitamin E herbal supplements, hormonal therapy/replacement or CYP3A4 substrates,&#xD;
             inducers and inhibitors within 14 days prior to the first dose of study medication.&#xD;
&#xD;
        Additional Exclusion Criteria for MAD Subjects with Presumptive NAFLD:&#xD;
&#xD;
          -  Subjects taking any antidiabetic medication.&#xD;
&#xD;
          -  Subjects with unstable proliferative retinopathy, macular oedema (fundus examination&#xD;
             performed in the previous year will be considered relevant on Investigator's&#xD;
             judgement).&#xD;
&#xD;
          -  Subject has taken fibrates, statins, and/or Vitamin E within 6 weeks prior to the&#xD;
             first dose administration.&#xD;
&#xD;
          -  Subjects with a history of bariatric surgery and any other gastrointestinal surgery&#xD;
             relative to weight loss.&#xD;
&#xD;
          -  Subjects with common causes of secondary hepatic steatosis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Dickerson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pharmaceutical Research Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pharmaceutical Research Associates, Inc.,</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>August 29, 2016</study_first_submitted>
  <study_first_submitted_qc>September 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2016</study_first_posted>
  <last_update_submitted>August 16, 2017</last_update_submitted>
  <last_update_submitted_qc>August 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>First-in-human</keyword>
  <keyword>Single Ascending Dose</keyword>
  <keyword>Multiple Ascending Dose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>When the clinical study report has been submitted to the appropriate Regulatory authorities, a lay person summary will be provided to all study subjects by mail or email.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

